The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA”) Approval of D-PLEX₁₀₀.; The Company Recently ...

The Montreal Protocol The Montreal Protocol on Substances that Deplete the Ozone Layer is the landmark multilateral environmental agreement that regulates the production and consumption of nearly 100 ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced ...

Akebia Therapeutics, Inc. announced the publication of pre-specified analyses from its global phase 3 clinical trials of vadadustat for treating anemia in chronic kidney disease (CKD) in the ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced drug can hold its own against FDA-approved products like Seysara and ...

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.

The aim of this phase 3 study is to confirm the efficacy and safety of relacorilant + nab-paclitaxel in a larger population. Methods: ROSELLA (NCT05257408) is a randomized, controlled, open-label, ...

ARASTEP, a phase 3 randomized, double-blind, placebo-controlled study (NCT05794906) that is actively recruiting, is set to evaluate the use of darolutamide (Nubeqa) plus androgen deprivation therapy ...